ENDOREX CORP
10QSB, EX-27, 2000-11-13
PHARMACEUTICAL PREPARATIONS
Previous: ENDOREX CORP, 10QSB, 2000-11-13
Next: ENDOREX CORP, 10QSB, EX-99.1, 2000-11-13



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET AND CONSOLIDATED STATEMENT OF OPERATIONS AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                      10,337,263
<SECURITIES>                                 3,015,443
<RECEIVABLES>                                  250,000
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            13,780,052
<PP&E>                                       1,150,228
<DEPRECIATION>                               (761,358)
<TOTAL-ASSETS>                              14,409,740
<CURRENT-LIABILITIES>                        2,647,187
<BONDS>                                              0
                        9,505,034
                                  9,845,122
<COMMON>                                        12,861
<OTHER-SE>                                 (7,845,084)
<TOTAL-LIABILITY-AND-EQUITY>                14,409,740
<SALES>                                              0
<TOTAL-REVENUES>                               549,527
<CGS>                                                0
<TOTAL-COSTS>                                2,146,304
<OTHER-EXPENSES>                             2,201,706
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              38,637
<INCOME-PRETAX>                            (3,837,120)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (3,837,120)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (3,837,120)
<EPS-BASIC>                                     (0.41)
<EPS-DILUTED>                                   (0.41)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission